Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 2 Interventional

Preventing Injured Knees From osteoArthritis: Severity Outcomes

ClinicalTrials.gov ID: NCT06096259

Public ClinicalTrials.gov record NCT06096259. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 12:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Preventing Injured Knees From osteoArthritis: Severity Outcomes (PIKASO)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is being done to find out if metformin is effective at reducing pain by delaying the onset of post-traumatic osteoarthritis (PTOA) after anterior cruciate ligament (ACL) reconstruction. This research study will compare metformin to placebo. The placebo tablet looks exactly like metformin, but contains no metformin. Placebos are used in research studies to see if the results are due to the study drug or due to other reasons. Metformin is approved by the U.S. Food and Drug Administration (FDA) to treat type II diabetes. Notably, it also has anti-inflammatory effects, suggesting it could benefit people who have an ACL injury and are undergoing ACL reconstruction.

Study identification

NCT ID
NCT06096259
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Enrollment
512 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 45 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 5, 2024
Primary completion
Nov 30, 2028
Completion
Nov 30, 2029
Last update posted
Apr 28, 2025

2024 – 2029

United States locations

U.S. sites
9
U.S. states
8
U.S. cities
9
Facility City State ZIP Site status
Emory University Atlanta Georgia 30322 Recruiting
University of Iowa Hospitals and Clinics Iowa City Iowa 52242 Recruiting
University of Kentucky Lexington Kentucky 40504 Recruiting
Brigham and Women's Hospital Boston Massachusetts 02115 Recruiting
University of Nebraska Medical Center Omaha Nebraska 68198 Recruiting
Hospital for Special Surgery New York New York 10021 Recruiting
The University of North Carolina at Chapel Hill Chapel Hill North Carolina 25599 Recruiting
Cleveland Clinic Cleveland Ohio 44195 Recruiting
The Ohio State University Columbus Ohio 43210 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06096259, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 28, 2025 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06096259 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →